BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis. 2009;68:1793-1794. [PMID: 19822717 DOI: 10.1136/ard.2008.105924] [Cited by in Crossref: 109] [Cited by in F6Publishing: 74] [Article Influence: 9.1] [Reference Citation Analysis]
Number Citing Articles
1 Fasoulakis Z, Antsaklis P, Galanopoulos N, Kontomanolis E. Common Adverse Effects of Anti-TNF Agents on Gestation. Obstet Gynecol Int 2016;2016:8648651. [PMID: 28044081 DOI: 10.1155/2016/8648651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Nast A, Smith C, Spuls P, Avila Valle G, Bata‐csörgö Z, Boonen H, De Jong E, Garcia‐doval I, Gisondi P, Kaur‐knudsen D, Mahil S, Mälkönen T, Maul J, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt K, Sator P, Schmitt‐egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021;35:281-317. [DOI: 10.1111/jdv.16926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
3 El Miedany Y, Palmer D. Rheumatology-led pregnancy clinic: enhancing the care of women with rheumatic diseases during pregnancy. Clin Rheumatol 2020;39:3593-601. [PMID: 32495228 DOI: 10.1007/s10067-020-05173-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Mena-vazquez N. Safety of biologic therapies during pregnancy in women with rheumatic disease. WJR 2015;5:82. [DOI: 10.5499/wjr.v5.i2.82] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Bangsgaard N, Rørbye C, Skov L. Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. Am J Clin Dermatol 2015;16:389-98. [PMID: 26149091 DOI: 10.1007/s40257-015-0137-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, Gottlieb AB, Koo JY, Lebwohl M, Leonardi CL, Van Voorhees AS, Bhushan R, Menter A. Research gaps in psoriasis: Opportunities for future studies. Journal of the American Academy of Dermatology 2014;70:146-67. [DOI: 10.1016/j.jaad.2013.08.042] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 10.1] [Reference Citation Analysis]
7 Saito J, Yakuwa N, Ishizuka T, Goto M, Yamatani A, Murashima A. Belimumab Concentrations in Maternal Serum and Breast Milk During Breastfeeding and the Safety Assessment of the Infant: A Case Study. Breastfeed Med 2020;15:475-7. [PMID: 32326740 DOI: 10.1089/bfm.2020.0068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. Birth Defects Research Part A: Clinical and Molecular Teratology 2012;94:607-11. [DOI: 10.1002/bdra.23033] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
9 Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C. German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 2: Treatment monitoring and specific clinical or comorbid situations. J Dtsch Dermatol Ges 2021;19:1092-115. [PMID: 34288477 DOI: 10.1111/ddg.14507] [Reference Citation Analysis]
10 Arnone M, Takahashi MDF, Carvalho AVE, Bernardo WM, Bressan AL, Ramos AMC, Terena AC, Souza CDS, Nunes DH, Bortoletto MCC, Oliveira MFSP, Neffá JM, Fieri LC, Azulay-Abulafia L, Felix PAO, Magalhaes RF, Romiti R, Jaime TJ. Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology. An Bras Dermatol 2019;94:76-107. [PMID: 31166402 DOI: 10.1590/abd1806-4841.2019940211] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
11 Rademaker M, Agnew K, Andrews M, Armour K, Baker C, Foley P, Frew J, Gebauer K, Gupta M, Kennedy D, Marshman G, Sullivan J. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol 2018;59:86-100. [PMID: 28543445 DOI: 10.1111/ajd.12641] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
12 Martin PL, Weinbauer GF. Developmental Toxicity Testing of Biopharmaceuticals in Nonhuman Primates: Previous Experience and Future Directions. Int J Toxicol 2010;29:552-68. [DOI: 10.1177/1091581810378896] [Cited by in Crossref: 60] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
13 Tada Y, Sakai M, Nakao Y, Maruyama A, Ono N, Koarada S. Placental transfer of tocilizumab in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2019;58:1694-5. [PMID: 31329987 DOI: 10.1093/rheumatology/kez155] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
14 Perng P, Zampella JG, Okoye GA. Management of hidradenitis suppurativa in pregnancy. Journal of the American Academy of Dermatology 2017;76:979-89. [DOI: 10.1016/j.jaad.2016.10.032] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
15 Babalola O, Strober BE. Management of psoriasis in pregnancy: Treatment of cutaneous disorders of pregnancy. Dermatol Ther 2013;26:285-92. [DOI: 10.1111/dth.12073] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
16 Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, Bressler B, Gooderham M, Ho V, Jamal S, Pope JE, Steinhart AH, Vinh DC, Wade J. Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. J Cutan Med Surg 2019;23:50-74. [PMID: 30463418 DOI: 10.1177/1203475418811335] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
17 Kerensky TA, Gottlieb AB, Yaniv S, Au S. Etanercept: efficacy and safety for approved indications. Expert Opinion on Drug Safety 2011;11:121-39. [DOI: 10.1517/14740338.2012.633509] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
18 Beltagy A, Aghamajidi A, Trespidi L, Ossola W, Meroni PL. Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road. Front Pharmacol 2021;12:621247. [PMID: 34122062 DOI: 10.3389/fphar.2021.621247] [Reference Citation Analysis]
19 Tam LS, Wei JC, Aggarwal A, Baek HJ, Cheung PP, Chiowchanwisawakit P, Dans L, Gu J, Hagino N, Kishimoto M, Reyes HM, Soroosh S, Stebbings S, Whittle S, Yeap SS, Lau CS. 2018 APLAR axial spondyloarthritis treatment recommendations. Int J Rheum Dis 2019;22:340-56. [PMID: 30816645 DOI: 10.1111/1756-185X.13510] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
20 Clowse ME. The use of anti-TNFα medications for rheumatologic disease in pregnancy. Int J Womens Health 2010;2:199-209. [PMID: 21072312 DOI: 10.2147/ijwh.s6029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
21 Natsumi I, Matsukawa Y, Miyagawa K, Kodaira H, Tanaka T, Horikoshi A, Takeuchi J, Takei M, Maejima M, Akimoto J. Successful childbearing in two women with rheumatoid arthritis and a history of miscarriage after etanercept treatment. Rheumatol Int 2013;33:2433-5. [DOI: 10.1007/s00296-012-2433-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
22 Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation. Journal of the American Academy of Dermatology 2014;70:417.e1-417.e10. [DOI: 10.1016/j.jaad.2013.09.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
23 Ling J, Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Review of Vaccines 2016;15:239-56. [DOI: 10.1586/14760584.2016.1115351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
24 De Lorenzo R, Ramirez GA, Punzo D, Lorioli L, Rovelli R, Canti V, Barera G, Rovere-Querini P. Neonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives. Pharmacol Res 2020;152:104583. [PMID: 31816434 DOI: 10.1016/j.phrs.2019.104583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ostensen M, Förger F. Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol. 2011;23:293-298. [PMID: 21346578 DOI: 10.1097/bor.0b013e328344a732] [Cited by in Crossref: 37] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
26 Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: a review (II). Actas Dermosifiliogr 2014;105:813-21. [PMID: 24314892 DOI: 10.1016/j.ad.2013.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Ara M, Daudén E. Etanercept for the treatment of psoriasis. Expert Review of Dermatology 2014;8:357-72. [DOI: 10.1586/17469872.2013.814880] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
28 Balbi GGM, Domingues V, Balbi GGM, De Jesús GR, Levy RA. Use of synthetic and biologic DMARDs during pregnancy. Expert Rev Clin Immunol 2019;15:27-39. [PMID: 30365902 DOI: 10.1080/1744666X.2019.1541739] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
29 Bermas BL. Lactation and Management of Postpartum Disease. Rheum Dis Clin North Am 2017;43:249-62. [PMID: 28390567 DOI: 10.1016/j.rdc.2016.12.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
30 Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53:1377-1385. [PMID: 24352337 DOI: 10.1093/rheumatology/ket409] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
31 Belinchón I, Velasco M, Ara-Martín M, Armesto Alonso S, Baniandrés Rodríguez O, Ferrándiz Pulido L, García-Bustinduy M, Martínez-López JA, Martínez Sánchez N, Pérez Ferriols A, Pérez Pascual E, Rivera Díaz R, Ruiz-Villaverde R, Taberner Ferrer R, Vicente Villa A, Carrascosa JM. Management of Psoriasis During Preconception, Pregnancy, Postpartum, and Breastfeeding: A Consensus Statement. Actas Dermosifiliogr (Engl Ed) 2021;112:225-41. [PMID: 33065101 DOI: 10.1016/j.ad.2020.10.002] [Reference Citation Analysis]
32 Pham-Huy A, Sadarangani M, Huang V, Ostensen M, Castillo E, Troster SM, Vaudry W, Nguyen GC, Top KA. From mother to baby: antenatal exposure to monoclonal antibody biologics. Expert Rev Clin Immunol 2019;15:221-9. [PMID: 30570400 DOI: 10.1080/1744666X.2019.1561282] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
33 Østensen M. The use of biologics in pregnant patients with rheumatic disease. Expert Rev Clin Pharmacol 2017;10:661-9. [PMID: 28326845 DOI: 10.1080/17512433.2017.1305268] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
34 Bae YC, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo B, Kimball AB. Review of treatment options for psoriasis in pregnant or lactating women: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology 2012;67:459-77. [DOI: 10.1016/j.jaad.2011.07.039] [Cited by in Crossref: 73] [Cited by in F6Publishing: 43] [Article Influence: 8.1] [Reference Citation Analysis]
35 Carman WJ, Accortt NA, Anthony MS, Iles J, Enger C. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf 2017;26:1109-18. [PMID: 28758274 DOI: 10.1002/pds.4261] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
36 Kivelevitch D, Mansouri B, Menter A. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics 2014;8:169-82. [PMID: 24790410 DOI: 10.2147/BTT.S41481] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
37 Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, Clowse M, Curtis JR, Dao K, Hankins GDV, Koren G, Kim SC, Lapteva L, Mahadevan U, Moore T, Nolan M, Ren Z, Sammaritano LR, Seymour S, Weisman MH. Proceedings From the American College of Rheumatology Reproductive Health Summit: The Management of Fertility, Pregnancy, and Lactation in Women With Autoimmune and Systemic Inflammatory Diseases: Pregnancy in Autoimmune and Systemic Inflammatory Diseases. Arthritis Care & Research 2015;67:313-25. [DOI: 10.1002/acr.22516] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
38 Fischer-Betz R, Østensen M. Biologics and small molecules in the management of psoriatic arthritis: Reproduction related issues in female and male patients. Expert Rev Clin Pharmacol 2021;14:979-89. [PMID: 33982647 DOI: 10.1080/17512433.2021.1925536] [Reference Citation Analysis]
39 Bowman CJ, Breslin WJ, Connor AV, Martin PL, Moffat GJ, Sivaraman L, Tornesi MB, Chivers S. Placental Transfer of Fc-Containing Biopharmaceuticals across Species, an Industry Survey Analysis: PLACENTAL TRANSFER OF Fc BIOPHARMACEUTICALS. Birth Defects Res B 2013;98:459-85. [DOI: 10.1002/bdrb.21089] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
40 Ergaz Z, Bar-Oz B, Vainer GW, Abu-Leil S, Simanovsky N, Diav-Citrin O. Congenital fulminant Kaposiform hemangioendothelioma of the leg. Reprod Toxicol. 2014;50:1-3. [PMID: 25277314 DOI: 10.1016/j.reprotox.2014.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Atzeni F, Sarzi-puttini P. Twelve years’ experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice. Expert Review of Clinical Immunology 2014;8:213-22. [DOI: 10.1586/eci.12.6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
42 Berthelsen BG, Fjeldsøe-Nielsen H, Nielsen CT, Hellmuth E. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology (Oxford). 2010;49:2225-2227. [PMID: 20581374 DOI: 10.1093/rheumatology/keq185] [Cited by in Crossref: 80] [Cited by in F6Publishing: 54] [Article Influence: 7.3] [Reference Citation Analysis]
43 Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78 Suppl 1:15-185. [PMID: 21703545 DOI: 10.1016/S1297-319X(11)70001-X] [Cited by in Crossref: 53] [Cited by in F6Publishing: 5] [Article Influence: 5.3] [Reference Citation Analysis]
44 Simon PC, Vallano A. [Anti-tumor necrosis factor-α medications and pregnancy]. Med Clin (Barc) 2013;141:257-9. [PMID: 23702347 DOI: 10.1016/j.medcli.2013.04.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
45 Small HY, Nosalski R, Morgan H, Beattie E, Guzik TJ, Graham D, Delles C. Role of Tumor Necrosis Factor-α and Natural Killer Cells in Uterine Artery Function and Pregnancy Outcome in the Stroke-Prone Spontaneously Hypertensive Rat. Hypertension 2016;68:1298-307. [PMID: 27733586 DOI: 10.1161/HYPERTENSIONAHA.116.07933] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
46 Nakajima K, Watanabe O, Mochizuki M, Nakasone A, Ishizuka N, Murashima A. Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan. Mod Rheumatol 2016;26:667-71. [PMID: 26873562 DOI: 10.3109/14397595.2016.1147405] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 9.4] [Reference Citation Analysis]
47 Soh MC, Moretto M. The use of biologics for autoimmune rheumatic diseases in fertility and pregnancy. Obstet Med 2020;13:5-13. [PMID: 32284726 DOI: 10.1177/1753495X19841799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Pham-Huy A, Top KA, Constantinescu C, Seow CH, El-Chaâr D. The use and impact of monoclonal antibody biologics during pregnancy. CMAJ 2021;193:E1129-36. [PMID: 34312166 DOI: 10.1503/cmaj.202391] [Reference Citation Analysis]
49 Eliesen GAM, van Drongelen J, van Hove H, Kooijman NI, van den Broek P, de Vries A, Roeleveld N, Russel FGM, Greupink R. Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused Placenta. Clin Pharmacol Ther 2020;108:99-106. [PMID: 32153014 DOI: 10.1002/cpt.1827] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
50 Ince-Askan H, Dolhain RJ. Pregnancy and rheumatoid arthritis. Best Pract Res Clin Rheumatol 2015;29:580-96. [PMID: 26697768 DOI: 10.1016/j.berh.2015.07.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
51 Rump JA, Schönborn H. [Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment]. Z Rheumatol. 2010;69:903-909. [PMID: 20532789 DOI: 10.1007/s00393-010-0652-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
52 Raja H, Matteson EL, Michet CJ, Smith JR, Pulido JS. Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding. Transl Vis Sci Technol 2012;1:6. [PMID: 24049706 DOI: 10.1167/tvst.1.2.6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
53 Furer V, Rondaan C, Heijstek MW, Agmon-levin N, van Assen S, Bijl M, Breedveld FC, D'amelio R, Dougados M, Kapetanovic MC, van Laar JM, de Thurah A, Landewé RB, Molto A, Müller-ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2019;79:39-52. [DOI: 10.1136/annrheumdis-2019-215882] [Cited by in Crossref: 193] [Cited by in F6Publishing: 117] [Article Influence: 96.5] [Reference Citation Analysis]
54 Gerosa M, Argolini LM, Artusi C, Chighizola CB. The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert Rev Clin Pharmacol 2018;11:987-98. [PMID: 30227748 DOI: 10.1080/17512433.2018.1525293] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
55 Hoxha A, Calligaro A, Di Poi E, Peccatori S, Favaro M, Del Ross T, Ramonda R, Grava C, Raffeiner B, Ravagni P, De Vita S, Ruffatti A. Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study. Joint Bone Spine 2017;84:169-73. [DOI: 10.1016/j.jbspin.2016.03.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
56 Levy RA, de Jesús GR, de Jesús NR, Klumb EM. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev 2016;15:955-63. [PMID: 27490204 DOI: 10.1016/j.autrev.2016.07.014] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
57 Krause ML, Amin S, Makol A. Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know. Ther Adv Musculoskelet Dis 2014;6:169-84. [PMID: 25342996 DOI: 10.1177/1759720X14551568] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
58 Fischer-Betz RE, Schneider M. [Biologics during pregnancy and breast--feeding]. Z Rheumatol 2010;69:780-7. [PMID: 21063826 DOI: 10.1007/s00393-010-0640-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
59 Sammaritano LR, Bermas BL. Rheumatoid arthritis medications and lactation. Current Opinion in Rheumatology 2014;26:354-60. [DOI: 10.1097/bor.0000000000000055] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 3.9] [Reference Citation Analysis]
60 Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2014;43:78-84. [PMID: 24284028 DOI: 10.1016/j.reprotox.2013.11.004] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
61 Puchner A, Gröchenig HP, Sautner J, Helmy-Bader Y, Juch H, Reinisch S, Högenauer C, Koch R, Hermann J, Studnicka-Benke A, Weger W, Puchner R, Dejaco C. Immunosuppressives and biologics during pregnancy and lactation : A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation.Wien Klin Wochenschr. 2019;131:29-44. [PMID: 30643992 DOI: 10.1007/s00508-019-1448-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
62 Keeling S, Wolbink GJ. Measuring multiple etanercept levels in the breast milk of a nursing mother with rheumatoid arthritis. J Rheumatol 2010;37:1551. [PMID: 20595298 DOI: 10.3899/jrheum.100077] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
63 Krause ML, Makol A. Management of rheumatoid arthritis during pregnancy: challenges and solutions. Open Access Rheumatol 2016;8:23-36. [PMID: 27843367 DOI: 10.2147/OARRR.S85340] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
64 Eworuke E, Panucci G, Goulding M, Neuner R, Toh S. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants. Pharmacoepidemiol Drug Saf 2019;28:296-304. [PMID: 30430682 DOI: 10.1002/pds.4695] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
65 Vinet É, De Moura C, Pineau CA, Abrahamowicz M, Curtis JR, Bernatsky S. Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort Study. Arthritis Rheumatol 2018;70:1565-71. [DOI: 10.1002/art.40536] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
66 Gerosa M, Schioppo T, Meroni PL. Challenges and treatment options for rheumatoid arthritis during pregnancy. Expert Opinion on Pharmacotherapy 2016;17:1539-47. [DOI: 10.1080/14656566.2016.1197204] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 4.4] [Reference Citation Analysis]
67 Förger F, Villiger PM. Treatment of rheumatoid arthritis during pregnancy: present and future. Expert Review of Clinical Immunology 2016;12:937-44. [DOI: 10.1080/1744666x.2016.1184973] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
68 Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-randone S, Matucci-cerinic M, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, Goletti D. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism 2016;45:519-32. [DOI: 10.1016/j.semarthrit.2015.10.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
69 Yiu ZZ, Griffiths CE, Warren RB. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. Br J Dermatol. 2014;171:485-491. [PMID: 24749725 DOI: 10.1111/bjd.13060] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
70 Johansen CB, Jimenez-Solem E, Haerskjold A, Sand FL, Thomsen SF. The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review. Int J Mol Sci 2018;19:E1349. [PMID: 29751529 DOI: 10.3390/ijms19051349] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
71 Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci. 2014;1317:32-38. [PMID: 24840548 DOI: 10.1111/nyas.12456] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
72 Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C. Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidität. J Dtsch Dermatol Ges 2021;19:1092-117. [PMID: 34288473 DOI: 10.1111/ddg.14507_g] [Reference Citation Analysis]
73 Hoffman MB, Farhangian M, Feldman SR. Psoriasis during pregnancy: characteristics and important management recommendations. Expert Review of Clinical Immunology 2015;11:709-20. [DOI: 10.1586/1744666x.2015.1037742] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
74 Giles I, Yee C, Gordon C. Stratifying management of rheumatic disease for pregnancy and breastfeeding. Nat Rev Rheumatol 2019;15:391-402. [DOI: 10.1038/s41584-019-0240-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]